ライフサイエンスコーパス: platelet count

1 international normalized ratio, fibrinogen, platelet count).

2 predicted by age, level of hemoglobin F, and platelet count.

3 bocytopenia, a disorder characterized by low platelet count.

4 tes of paroxysmal atrial fibrillation, lower platelet count.

5 patients who require therapy to increase the platelet count.

6 orrelated well with levels of fibrinogen and platelet count.

7 11 or 12) and decreased hemoglobin level and platelet count.

8 ratio of aspartate aminotransferase level to platelet count.

9 phenotypes prompted a revision incorporating platelet count.

10 on levels were significantly associated with platelet count.

11 e, defined as confirmed normalization of the platelet count.

12 y of survival along with multinodularity and platelet count.

13 unoglobulin is commonly used to increase the platelet count.

14 terpretable liver stiffness measurements and platelet counts.

15 between blood dose and dose rate, RIFs, and platelet counts.

16 dose significantly correlated with decreased platelet counts.

17 riched for platelet function, independent of platelet counts.

18 ing disorder characterized by abnormally low platelet counts.

19 of the underlying disease will also increase platelet counts.

20 ld revise PERSEVERE to incorporate admission platelet counts.

21 rget retaining potential for enhancing human platelet counts.

22 n and function and correlates with increased platelet counts.

23 ccompanied by a transient drop in peripheral platelet counts.

24 g MK transcriptomes and miRs associated with platelet counts.

25 bition of miR-125a-5p in vivo lowered murine platelet counts.

26 ose adjustments were allowed weekly based on platelet counts.

27 ve higher plasma fibrinogen levels and lower platelet counts.

28 ; prevalence increased with decreasing nadir platelet count (0/4, >=15 x 109/L; 2/9, 10-14 x 109/L; 4

29 load, aspartate aminotransferase levels, and platelet counts; 13 of 106 (12.3%) subjects had TE measu

30 hrombocytopenia (hemoglobin level, 9.4 g/dL; platelet count, 16 x 10(9)/L); these were refractory to

31 dex (2.14 versus 0.74, P = 0.0003) and lower platelet counts (205 versus 293, P = 0.02).

32 rtant whereas cytopenias were less profound (platelet count, 22 x 103/mm3 [9-57] vs 13 x 103/mm3 [9-2

33 l calprotectin, C-reactive protein, albumin, platelet count, 25(OH) vitamin D, or 1,25(di-OH) vitamin

34 bocytopenia aged 1 year to 17 years and mean platelet counts 30 x 10(9)/L or less (mean of two measur

35 absolute neutrophil count (4100/microL), and platelet count (362 x 103/microL) were identified in mod

36 .6] in the placebo group), mean (SD) initial platelet count (59.5 x 10(9)/L [43.3] vs 63.7 x 10(9)/L

37 , hypophosphatemia (11 [19%]), and decreased platelet count (8 [14%]).

38 ant was associated with a 42% lower baseline platelet count (95% CI, -5% to -65%: P Value = 0.03).

39 cribed coding variants associated with lower platelet count: a common missense variant in CPS1 (rs104

40 associated with faster normalization of the platelet count; a lower incidence of a composite of TTP-

41 iver stiffness measurements below 20 kPa and platelet counts above 150,000 (favorable Baveno VI statu

42 beta3, myosin IIa, FXIIIa cross-linking, and platelet count all promote 1 or more phases of the clot

43 Data from a substudy of platelet counts among newborns are also presented.

44 cause bleeding occurred over a wide range of platelet counts among patients undergoing allogeneic SCT

45 aximum amplitude, a factor of fibrinogen and platelet count and function, and a measure of clot stren

46 rity score, Glascow Coma Scale, base excess, platelet count and hemoglobin, adrenaline, and syndecan-

47 associated with chest tube bleeding, whereas platelet count and hemostatic tests were not.

48 ration, but negatively correlates with human platelet count and inhibits MK PP formation (PPF).

49 h Indian meat eaters, vegetarians had higher platelet count and lower volume.

50 ific responses to vaccinations, and improved platelet count and mean platelet volume normalisation.

51 Platelet count and P-selectin (a ubiquitous cargo of alp

52 inflammation and organ function such as CRP, platelet count and serum lactate have to be taken into a

53 enhanced response to agonists in vitro, but platelet count and survival are normal.

54 These mice displayed normal platelet counts and a slight reduction in platelet volum

55 management of patients with persistently low platelet counts and bleeding.

56 Cdkn2a-deficient strains exhibited increased platelet counts and bone marrow megakaryopoiesis.

57 penia, which quickly relapses back to normal platelet counts and deficient plasma VWF.

58 ding substantial decreases in lymphocyte and platelet counts and dysregulation of key biochemical mar

59 h eaters, and vegans had significantly lower platelet counts and higher platelet volume, whereas vege

60 Similarly, adult THS exposure also decreased platelet counts and increased neutrophil counts.

61 tent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding.

62 penia and is clinically effective in raising platelet counts and reducing bleeding events.

63 LLLT significantly lifted the nadir of platelet counts and restored tail bleeding time when app

64 and non-meat eaters, and differences in mean platelet counts and volume between diet groups, warrant

65 globin, red and white blood cell counts, and platelet counts and volume in regular meat eaters (>3 ti

66 iplasmin, antitrombin, prothrombin time, and platelet count) and the DIC score according the Internat

67 ts (international normalized ratio [INR] and platelet count), and its use may avoid unnecessary blood

68 heritability to interindividual variation in platelet count, and better understanding of the regulati

69 Hemoglobin level, platelet count, and body mass index were excluded from t

70 te of 49.2% for all thrombotic, coagulation, platelet count, and function disorder patients and a rat

71 anced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase

72 d active alcoholism (37% versus 10%), higher platelet count, and lower hematocrit at admission in the

73 Age, sex, platelet count, and mean platelet volume were similar be

74 levels, on blood-cell-related traits such as platelet count, and on disease traits such as coronary a

75 ndomisation was stratified by risk category, platelet count, and region.

76 Mean hemoglobin concentration, platelet count, and spleen and liver volumes remained st

77 measurement [LSM] by transient elastography, platelet count, and spleen diameter with calculation of

78 ised leukocyte counting and differentiation, platelet counting, and the quantification of 13 proinfla

79 e bone marrow, completely reconstitute blood platelet counts, and contribute to multiple haematopoiet

80 rombocytopenia showing a marked reduction in platelet counts, and dengue hemorrhagic fever.

81 tively show declining fibrinogen, increasing platelet counts, and lower white blood cell counts.

82 od cell parameters but normal neutrophil and platelet counts, and reduced overall survival.

83 nt; four experienced significantly increased platelet counts, and ten had reduced platelet transfusio

84 egulated inflammatory state, and a decreased platelet count are all hallmarks of severe invasive Stre

85 ecause current treatment guidelines based on platelet count are confounded by variable bleeding pheno

86 gle-centre study to demonstrate that RDW and platelet count are independent predictors of long-term a

87 ombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial prese

88 mes as likely to have a normalization of the platelet count as those who received placebo.

89 model consisted of the baseline albumin and platelet count, as well as the bilirubin, transaminases,

90 tifier [ESDI]) included history of vomiting, platelet count, AST level.

91 iplostim-treated patients (N = 52), the mean platelet count at 2 weeks of treatment was 141,000/muL.

92 ndothelium-derived CD105-microparticles, and platelet count at admission could predict the absence of

93 ater than or equal to 9 g/dL (2 points), and platelet count at admission greater than 250,000/muL (1

94 significantly higher levels of CRP and lower platelet count at baseline (CRP 262 mg/L (IQR 101-307) v

95 Mean maternal platelet count at birth did not differ between groups (I

96 d cell count, absolute neutrophil count, and platelet count at commonly used thresholds for IBIs.

97 The mean platelet count at enrollment was 62,000/muL.

98 d cell count at least 3 x 10(9) cells per L, platelet count at least 100 x 10(9) platelets per L, and

99 k cytogenetic abnormalities at diagnosis and platelet count at randomization (as surrogate for CR vs

100 lower nadir platelet count (P = .005), lower platelet count at time of neuroimaging (P = .029), and h

101 n the MK growth in cultures and the infants' platelet counts at birth.

102 We found that lower platelet counts at time of CAR T-cell infusion were asso

103 (hazard ratio, 1.65; 95% CI, 1.31-2.08 for a platelet count below 50,000/mm3 vs > 150,000/mm3; p < 0.

104 Baseline biopsy stage F3 or F4 and platelet count below normal were the strongest predictor

105 No patients in the placebo group had platelet counts below 100,000 per microliter, whereas 15

106 No patient had platelet counts below 50,000 per microliter after enhanc

107 Platelet counts between 6 x 10(9)/L and 80 x 10(9)/L wer

108 edictors included age, preoperative albumin, platelet count, bilirubin, surgery category, emergency i

109 aryocytes (MKs) deficient in miRs have lower platelet counts, but information about the role of miRs

110 telets from healthy donors in vitro, raising platelet counts by 0% (unsupplemented control), 25%, 50%

111 such as absolute neutrophil, lymphocyte, and platelet counts, C-reactive protein, albumin, bilirubin,

112 In times of physiological stress, platelet count can transiently rise.

113 iance was used to compare the time course of platelet count changes between survivors and nonsurvivor

114 associated with chest tube bleeding, whereas platelet count, coagulation tests, heparin dose, and thr

115 nse (CR; 54%), 5 CR with partial recovery of platelet count (CRp; 14%), and 5 CR with incomplete bloo

116 etrimental animal physiology was observed as platelet counts, d-dimer, fibrinogen levels, and serum c

117 n (general physical health deterioration and platelet count decreased).

118 IPC is the strongest independent platelet count-derived predictor of antiplatelet respons

119 ificant correlation between miRNA levels and platelet counts despite post-thaw processing.

120 If the platelet count does not increase after transfusion of 2

121 hat CCL5 signaling through CCR5 may increase platelet counts during physiological stress.

122 logistic model, a history of vomiting, lower platelet count, elevated aspartate aminotransferase (AST

123 ude a lack of bleeding risk, only mildly low platelet counts, elevated plasma fibrinogen levels, and

124 edictor of a hypercoagulable TEG profile and platelet count, endotoxin, Protein C and fibrinogen were

125 Nadir platelet counts for most affected neonates occurred at b

126 l, 259 patients (85.8%) achieved a response (platelet count >/=50 x 10(9)/L at least once in the abse

127 .2 g/dL (OR, 12.48; 95% CI, 3.86-40.33), and platelet count >10(5) cells/microL (OR, 7.44; 95% CI, 3.

128 he best new expanded classification rule was platelet count >110 x 10(9) cells/L and LSM <25 kPa.

129 can safely avoid screening endoscopy with a platelet count >150 x 10(9) cells/L and a liver stiffnes

130 f thrombosis during hospitalization included platelet count >450 x 109/L (adjusted OR, 3.56 [95% CI,

131 in advanced liver disease: hematocrit >=25%, platelet count >50,000, and fibrinogen >120 mg/dL.

132 as achievement of weekly platelet responses (platelet counts >/=50 x 10(9)/L without rescue drug use

133 idence interval [CI], 2.0-4.8) compared with platelet counts >/=81 x 10(9)/L.

134 Platelet count had a biphasic temporal pattern with an i

135 Median platelet count had dropped from 220.5 G/L before extraco

136 At the last follow-up visit, the platelet count had increased to 20-50 x 10(9) per L in o

137 Platelet counts had a nadir at day 3 followed by a rebou

138 ed on peripheral neutrophil, lymphocyte, and platelet counts has shown a prognostic impact in various

139 sed on liver stiffness measurement (LSM) and platelet count, have been proposed to avoid unnecessary

140 azards ratio, 0.98; p = 0.002) and decreased platelet count (hazards ratio, 1.19; p = 0.03) were asso

141 olysis, elevated liver enzyme level, and low platelet count (HELLP) syndrome (3 women had used LMWH);

142 Scale, systolic blood pressure, base excess, platelet count, hemoglobin, prehospital plasma, and preh

143 ucerase enzyme therapy in maintaining stable platelet counts, hemoglobin concentrations, and spleen a

144 gulopathy (prolonged aPTT and INR, decreased platelet count), hepatic injury (high bilirubin), circul

145 After adjustment for platelet count, higher levels of thrombin receptor activ

146 crement increase), higher prelymphodepletion platelet count (HR, 0.74 per 50 000/muL increment increa

147 hite blood cell count (HR, 1.910; P = .017), platelet count (HR, 7.437; P = .005), and Ph-like ALL (H

148 , but both LSPS and a model combining TE and platelet count identified patients with very low risk (<

149 performed a genome-wide association study of platelet count in 12,491 participants of the Hispanic Co

150 ed platelet clearance resulting in increased platelet count in a mouse model of sepsis.

151 the findings for the other groups, the mean platelet count in the 9.3-GBq group decreased chronicall

152 The mean platelet count in the eight observation patients at 3 we

153 otransferase in two (8%) patients, decreased platelet count in two (8%) patients, and hypophosphataem

154 l, factor VII level and white blood cell and platelet counts in 15 755 individuals across three ances

155 the risk block, and has been associated with platelet counts in humans.

156 An analysis of platelet counts in infants born to mothers following ant

157 and hematocrit parameters but increased the platelet counts in Jak2V617F knock-in mice.

158 of Hmga2 resulted in increased chimerism and platelet counts in recipients of retrovirally transduced

159 his correlated with normalization of in vivo platelet counts in the transferred SCID mice suggesting

160 16 mg/kg) every 3 days gradually lowered the platelet count; in this case, opsonized platelets were o

161 Median platelet counts increased to 50 x 10(9)/L or more by wee

162 The primary end point was the platelet count increment 10 to 90 minutes following tran

163 There was no significant difference in platelet count increment 10 to 90 minutes following tran

164 rom low-responder donors, resulting in lower platelet count increments following transfusion.

165 ed a mortality score incorporating age, sex, platelet count, international normalised ratio, and obse

166 ormed by dividing patients based on baseline platelet count into two groups (cutoff 150x10(9) /L) dem

167 ormed by dividing patients based on baseline platelet count into two groups (cutoff, 150 x 10(9) /L)

168 hole blood flow cytometry: absolute immature platelet count (IPC), immature platelet fraction, and hi

169 While a lower platelet count is associated with severity and mortality

170 Measuring platelet count is inexpensive and easily feasible for th

171 A low platelet count is often an incidental feature, but it mi

172 Thrombocytopenia, a reduction in circulating platelet counts, is the most consistent sign of DENV-ind

173 ary or secondary immune thrombocytopenia and platelet counts less than 100 x 10(9) cells per L before

174 PO(a)-L(Rx) dose and placebo with respect to platelet counts, liver and renal measures, or influenza-

175 Karnofsky performance status lower than 90%, platelet count lower than 150 x 10(9)/L, leukocyte count

176 Responses in patients with platelet counts lower than 15 x 10(9)/L, more previous t

177 ve intent chemotherapy), laboratory-related (platelet count < 50 x 109/L, albumin below normal, LDH a

178 One patient with cirrhosis (with baseline platelet count <150 000 platelets/microL and albuminemia

179 counts were available, 56 (28%) had a birth platelet count <150 x 10(9)/L and 18 (9%) had platelet c

180 e (10.82 [1.49-78.69] per 1 mg/dL increase), platelet count <250 x 103/muL (1.92 [1.02-3.60]), lower

181 Bleeding on admission, platelet count <30 < 10(9) /L, fibrinogen level <60 mg/d

182 equire cytotoxic treatment and should have a platelet count <30 x 109/L or have symptoms of bleeding.

183 hy (defined in this study as INR >1.8 and/or platelet count <50 x 10(9) /L) who will be undergoing an

184 of blood for patients with thrombocytopenia (platelet count <=50 x 10(9)/L), anemia (hemoglobin <=10

185 In the propensity matched cohort, platelet counts < 50 x 10(9)/L were associated with incr

186 ocytopenia due to bone marrow insufficiency (platelet counts <25 x 10(9) per L) or grade 4 thrombocyt

187 tive study of 49 patients with ITP and nadir platelet counts <30 x 109/L and 18 aged-matched healthy

188 Sepsis patients with platelet counts <50 x 10(9)/L and 50 x 10(9) to 99 x 10(

189 latelet count <150 x 10(9)/L and 18 (9%) had platelet counts <50 x 10(9)/L.

190 trombopag or placebo, stratified by baseline platelet count (<10 x 10(9) platelets per L vs >/=10 x 1

191 R, 1.55; 95% CI, 1.02; 2.36; P = 0.041); low platelet count (<100 Giga/mm(3) : HR, 2.70; 95% CI, 1.62

192 PhtdSer; odds ratio, 1.67; p < 0.01), platelets count (</= 127 g/L; odds ratio, 0.99; p < 0.01

193 awal of antiangiogenic therapy, and lowering platelet counts markedly inhibited tumor rebound after w

194 valence of thromboembolic events and reached platelet count nadir later.

195 at birth, although for some neonates, nadir platelet counts occurred up to 6 days postnatally.

196 erval: 0.49, 0.95]; P = .022), and decreased platelet count (odds ratio, 0.99 [95% confidence interva

197 Poor platelet recovery was defined as a platelet count of <=20 000/muL on Day 2.

198 bin of 11 g/dL or lower (1.71, 1.13-2.57), a platelet count of 100 x 10(9) per L or lower (1.63, 1.13

199 ed weekly titrated romiplostim with a target platelet count of 100,000/muL or more, or were monitored

200 priate for most asymptomatic patients with a platelet count of 20 to 30 x 10(9)/L or higher.

201 /L (reference range, [3.4-9.7] x 10(9)/L), a platelet count of 223 x 10(9)/L (reference range, [158-4

202 une 2011 to have mild thrombocytosis, with a platelet count of 405,000.

203 In November 2011, repeat analysis revealed a platelet count of 433,000, and by February 2012 her plat

204 t 1 x 10(3) cells per mm(3) or higher, and a platelet count of 80 000/mm(3) or higher.

205 tinine clearance of at least 1.0 mL/s, and a platelet count of at least 50 x 10(9) per L.

206 atelet transfusion, symptomatic bleeding, or platelet count of less than 10 x 10(9) per L.

207 ss B disease, age greater than 65 years, and platelet count of less than 150 g/L (P < .003).

208 By multivariate Cox regression, a platelet count of less than or equal to 100,000/mm3 was

209 Patients with a stable platelet count of lower than 30 x 10(9) platelets per L,

210 had a greatly increased risk of bleeding at platelet counts of </=5 x 10(9)/L (odds ratio [OR], 3.1;

211 of eltrombopag was effective in maintaining platelet counts of 50 x 10(9)/L or more and reducing ble

212 weekly from 1 mug/kg to 10 mug/kg to target platelet counts of 50-200 x 10(9)/L.

213 rade 3 or worse haemorrhagic adverse events; platelet counts of less than 10 x 10(9) per L; or platel

214 were ineligible for standard treatments; had platelet counts of less than 30 x 10(9) platelets per L;

215 nt covariates, we investigated the impact of platelet count on 90-day mortality.

216 n against ECM, no significant differences in platelet counts or blood parasitemia levels were observe

217 tional status, plasma exchange/infusion use, platelet count, or lactate dehydrogenase or haptoglobin

218 h regard to their leukocyte, hematocrit, and platelet counts over time.

219 gher in women (P = 0.007) and increased with platelet count (P < 0.0001), whereas it was inversely as

220 1), percentage of lymphocytes (p = 0.03) and platelet count (p < 0.001) predicted all-cause mortality

221 nomegaly (P = 0.01) on ultrasound, and lower platelet count (P < 0.001) than those with subclinical P

222 disease duration (P = 7 x 10-6), lower nadir platelet count (P = .005), lower platelet count at time

223 ultivariate logistic regression revealed low platelet count (p = 0.

224 Interestingly, RDW (p = 0.004) and platelet count (p = 0.008) were independent predictors o

225 latelet goal (p = 0.009), but not with total platelet count (p = 0.75).

226 (P = 0.027), bilirubin (P = 0.005), and low platelet counts (P > 0.0001) were predictive of digestiv

227 n-positive tumors had lower peripheral blood platelet counts (P < .001) and higher D-dimer levels (P

228 wer HSCs had lower hemoglobin (P = 0.05) and platelet counts (P = 0.05) and showed early graft dysfun

229 acid tests [NAT]), liver function tests, and platelet counts; patient age was also determined.

230 NLR), platelet-to-lymphocyte ratio (PLR) and platelet count (PC) were shown to be prognostic in sever

231 od counts, specifically with measurements of platelet count (PLT) and mean platelet volume (MPV).

232 Mean platelet volume (MPV) and platelet count (PLT) are platelet measures that have bee

233 low-frequency (1% < MAF < 5%) variants with platelet count (PLT), red blood cell indices (MCH and MC

234 LSM combined with platelet count predicted a risk <5% of VNT in 30% of the

235 To account for baseline differences besides platelet counts, propensity matching was performed, afte

236 while a weak correlation was found with the platelet count (r = 0.257).

237 astography (TE) and von Willebrand factor to platelet count ratio (VITRO) as noninvasive methods for

238 efined as an aspartate transaminase level to platelet count ratio index [APRI] of >/=1.5) by IFN-lamb

239 Post-LT total platelet count recovered faster in the NEVLP than in the

240 was established, reverting to normal as the platelet count recovered.

241 ebrand factor-platelet interaction to hasten platelet count recovery and reduce mortality and TTP-rel

242 lete remission with incomplete neutrophil or platelet count recovery.

243 lete remission with incomplete neutrophil or platelet count recovery.

244 d severity and frequency of bleeding events, platelet counts remain low in GT-treated patients.

245 did the proportion of mothers who achieved a platelet count response (IVIg 38% vs corticosteroids 39%

246 In an in vivo murine acute colitis model, platelet count significantly correlated with inflammatio

247 Longitudinally, mean platelet counts significantly declined in the CFLD group

248 LPS exposure caused splenic hypertrophy and platelet count suppression.

249 (hemolysis, elevated liver enzymes, and low platelet count) syndrome are pregnancy-related complicat

250 ary outcome was achievement of perioperative platelet count targets (90 x 10(9) cells per L before ma

251 Deceased CFLD patients had lower platelet counts than those alive with CFLD (143 versus 2

252 Patients with retinal hemorrhages had lower platelet counts than those without (median, 22 vs 43 x 1

253 treated with an Ezh2 inhibitor showed higher platelet counts than vehicle controls.

254 uced platelet survival and a 40% decrease in platelet count that can be partially reversed with aspir

255 RGS18-/- mice have a 15% reduction in platelet count that is not affected by antiplatelet agen

256 eous group of disorders characterized by low platelet count that may result in bleeding tendency.

257 esponsive to the agonists independently from platelet count; this phenomenon was blunted by incubatio

258 tansine plus pertuzumab group were decreased platelet count (three [1%] of 223 patients vs 11 [5%] of

259 omboplastin time (four [10%]), and decreased platelet count (three [7%]) in the bone sarcoma group, a

260 Maintaining a higher platelet count threshold (</=20 x 109/L or </=30 x 109/L

261 sults suggest that a 25 x 109/L prophylactic platelet count threshold can be adopted in all preterm n

262 What is the optimal platelet count threshold for prophylactic platelet trans

263 hose who received platelet transfusions at a platelet-count threshold of 25,000 per cubic millimeter.

264 signed to receive platelet transfusions at a platelet-count threshold of 50,000 per cubic millimeter

265 Prophylactic platelet transfusion at defined platelet count thresholds is still recommended for pedia

266 veloped to receive a platelet transfusion at platelet-count thresholds of 50,000 per cubic millimeter

267 or greater than or equal to 50% decrease in platelet count to less than 100 cells/muL (Centers for D

268 Comparison of platelet count trends revealed that there was no statist

269 Using platelet count trends to guide decision to test for hepa

270 tabine plus berzosertib group) and decreased platelet count (two [6%] vs eight [24%]).

271 ts with higher levels of liver stiffness and platelet counts (unfavorable Baveno VI status).

272 induced thrombocytopenia testing results and platelet count variables were obtained from the electron

273 sepsis patients were stratified according to platelet counts (very low <50 x 10(9)/L, intermediate-lo

274 t count of 433,000, and by February 2012 her platelet count was 509,000.

275 , the impact of C-reactive protein (CRP) and platelet count was also analysed.

276 Platelet count was normal in Chk knockout (KO) mice, red

277 Although a significant recovery of the platelet count was observed in survivors, a recovery did

278 The median time to normalization of the platelet count was shorter with caplacizumab than with p

279 dition, we found that neither hematocrit nor platelet count was significantly associated with the haz

280 ed neutrophil-to-lymphocyte ratio (dNLR) and platelet counts was significantly associated with HPD st

281 Severity of cirrhosis and platelet count were comparable between groups.

282 the intensive care unit, and fibrinogen and platelet count were identified as the best routine coagu

283 lpha-fetoprotein, up-to-7 criteria, TTV, and platelet count were predictors of successful downstaging

284 e derived neutrophil-to-lymphocyte ratio and platelet count were significantly associated with HPD st

285 of C-reactive protein, body mass index, and platelet count were used to develop the COPPS system.

286 al hemorrhage was noted in 2 neonates (nadir platelet counts were 135 and 18 x 10(9)/L).

287 or east Asians) or placebo once daily, until platelet counts were 200 x 10(9)/L or higher, until remi

288 Of 203 neonates in whom platelet counts were available, 56 (28%) had a birth pla

289 Before gene therapy, platelet counts were lower than 20 x 10(9) per L in seve

290 times above the upper limit of normal and if platelet counts were lower than 90 000 per muL, or if th

291 In addition, higher platelet counts were observed among recipients who achie

292 her, while hematocrit, mean cell volume, and platelet counts were significantly lower compared to con

293 itters had significant reductions in WBC and platelet counts whereas five non-remitters did not.

294 (DNL), albeit with concomitant reductions in platelet count, which were attributed to the inhibition

295 suggest that clonal evolution or decreasing platelet counts while on ruxolitinib therapy may be mark

296 lood cell (RBC), white blood cell (WBC), and platelet counts with an accuracy > 95% as compared to an

297 outcome was the time to normalization of the platelet count, with discontinuation of daily plasma exc

298 tients (93%) experienced correction of their platelet count within 3 weeks, compared with one of eigh

299 The primary end point was correction of platelet count within 3 weeks.

300 mpared to SOC (transfusion guided by INR and platelet count), without an increase in bleeding complic